You are here

Study Shows Effects of Treatment With Abilify Maintena (Aripiprazole) on Psychiatric Hospitalization Rates in Schizophrenia Patients

Hospitalizations are significantly reduced compared with patients receiving oral antipsychotics

Results from a preliminary analysis have shown statistically significant reductions (P

The data were presented at the 166th American Psychiatric Association (APA) Annual Meeting in San Francisco in May, and were published in the Journal of Medical Economics.

The multicenter, open-label, North American study assessed total psychiatric hospitalization rates (defined as the proportion of patients with one or more inpatient psychiatric hospitalizations). The study was divided into two treatment periods: the first was a retrospective, 6-month period that assessed total psychiatric hospitalization rates in stable adult patients with schizophrenia treated with oral SOC antipsychotics; the second treatment period included the same patients, who were then converted to treatment with Abilify Maintena 400 mg once monthly for 6 months in the following prospective phases:

  • Phase A (1 to 4 weeks): a conversion phase in which patients cross-titrated from their current oral antipsychotic to oral aripiprazole;
  • Phase B (24 weeks): an open-label treatment phase where patients received Abilify Maintena (400 mg with an option to decrease to 300 mg for tolerability). As part of the study design, patients also received concomitant oral aripiprazole for the first 14 days of Phase B; and:
  • Phase C: an ongoing extension phase.

A total of 183 patients entered the prospective Phase B of the study, with 121 completing 3 months or more of treatment with Abilify Maintena.

The total psychiatric hospitalization rate for the retrospective 3-month analysis period, in which patients received oral SOC antipsychotics, was 28.1% (34/121) compared with a hospitalization rate of 6.6% (8/121) during the last 3 months of the prospective analysis period with Abilify Maintena (P P

The most common treatment-emergent adverse events observed during the prospective Phase B were psychotic disorder (7.7%), insomnia (7.2%), akathisia (7.2%), and schizophrenia, paranoid type (5.5%). The incidence of weight change was 2.2% gained weight and 2.2% lost weight.

Sources: Otsuka Pharmaceutical Co.; and Journal of Medical Economics.

Recent Headlines

Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Vitamin E Found in Samples Around the Country
Study Links Them to Premature Death
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut